Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead’s chief operating officer Bruce Given, M.D., will present at the 2015 RBC Capital Markets' Global Healthcare Conference on February 24, 2015 at 4:35 p.m. EST. Investors may access live and archived versions of the audio webcast of this presentations on the Company's website at http://ir.arrowheadresearch.com/events.cfm.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm.

Source: Arrowhead Research Corporation

Arrowhead Research CorporationVince Anzalone, CFA626-304-3400ir@arrowres.comorInvestor Relations:The Trout GroupLauren Glaser646-378-2972ir@arrowres.comorMedia:Russo PartnersMatt Middleman, M.D.212-845-4272matt.middleman@russopartnersllc.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Arrowhead Pharmaceuticals Charts.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Arrowhead Pharmaceuticals Charts.